[Skip to Content]
[Skip to Content Landing]
Views 1,373
Citations 0
Research Letter
June 24, 2019

Adoption of Digital Breast Tomosynthesis in Clinical Practice

Author Affiliations
  • 1Section of General Internal Medicine, Yale School of Medicine, New Haven, Connecticut
  • 2Department of Obstetrics, Gynecology, and Reproductive Sciences, Yale School of Medicine, New Haven, Connecticut
  • 3Department of Radiology and Biomedical Imaging, Yale School of Medicine, New Haven, Connecticut
  • 4Department of Health Policy and Management, Yale School of Public Health, New Haven, Connecticut
  • 5National Clinician Scholars Program, Yale School of Medicine, New Haven, Connecticut
JAMA Intern Med. 2019;179(9):1292-1295. doi:10.1001/jamainternmed.2019.1058

Although digital mammography has been widely used for breast cancer screening for more than a decade, it has imperfect sensitivity and specificity. A newer technology, digital breast tomosynthesis (DBT), may have a lower recall rate and a higher cancer detection rate than 2-dimensional mammography, although most studies of DBT were retrospective and did not evaluate long-term health outcomes.1 The use of DBT has some important trade-offs compared with 2-dimensional mammography, including higher costs and higher radiation dose with some machines.2 Although the US Preventive Services Task Force and the American Cancer Society have not specifically endorsed DBT for routine breast cancer screening, citing insufficient evidence, the American College of Radiology supports its use.3,4 Our objectives were to describe adoption of DBT for breast cancer screening in a large privately insured population, characterize regional patterns of adoption, and identify regional-level characteristics associated with that adoption.

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words